Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY: CYP-1020 in Schizophrenia
NCT01363349Phase 3Terminated
- Sponsor
- BioLineRx Ltd.
- Start
- May 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of BL-1020 in schizophrenia (2 arms), sponsored by BioLineRx Ltd. Primary endpoint: Cognition at 6 weeks. Started May 2011; status: terminated.
02
Drugs
BL-1020
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01363349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01363349.